Conservative management of malignant colorectal polyps in select cases is safe in long-term follow-up: An institutional review

Published:February 28, 2022DOI:


      • Little data on omitting resection for early-stage malignant colorectal polyps.
      • Patient selection critical when pursuing organ-sparing strategies.
      • Survival with non-operative management equivalent in select settings.



      Non-operative management of early-stage polypectomy-identified colorectal cancer (CRC) may be a safe alternative, but limited data exist.


      We compared outcomes between adults with post-polypectomy CRC who did and did not ultimately undergo resection from 2003 to 2018. Overall (OS) and recurrence-free (RFS) survival were calculated via log rank analysis using the Mantel-Cox method and plotted on Kaplan-Meier curves with significance evaluated at P < 0.05.


      N = 78 patients were included, most commonly with rectal/rectosigmoid CRC (45%). Almost half (47%) had resections, and the remaining 41 patients (53%) underwent organ-sparing techniques. Chemoradiation was administered to 5 of these 41 patients (12%), all with rectal cancer. At median follow-up of 52 months, 5-year OS and RFS were 78% and 100% with no significant differences when compared to resection (all P > 0.1).


      Using evidence-based patient selection and adjuvant therapy, organ-sparing management provides equal survival when compared to resection for post-polypectomy CRC.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Haggitt R.C.
        • Glotzbach R.E.
        • Soffer E.E.
        • Wruble L.D.
        Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy.
        Gastroenterology. 1985; 89: 328-336
        • Kikuchi R.
        • Takano M.
        • Takagi K.
        • et al.
        Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines.
        Dis Colon Rectum. 1995; 38: 1286-1295
        • Butte J.M.
        • Tang P.
        • Gonen M.
        • et al.
        Rate of residual disease after complete endoscopic resection of malignant colonic polyp.
        Dis Colon Rectum. 2012; 55: 122-127
        • Okabe S.
        • Shia J.
        • Nash G.
        • et al.
        Lymph node metastasis in T1 adenocarcinoma of the colon and rectum.
        J Gastrointest Surg. 2004; 8 (discussion 9-40): 1032-1039
        • Hassan C.
        • Zullo A.
        • Risio M.
        • Rossini F.P.
        • Morini S.
        Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis.
        Dis Colon Rectum. 2005; 48: 1588-1596
        • Levic K.
        • Bulut O.
        • Hansen T.P.
        • Gogenur I.
        • Bisgaard T.
        Malignant colorectal polyps: endoscopic polypectomy and watchful waiting is not inferior to subsequent bowel resection. A nationwide propensity score-based analysis.
        Langenbeck's Arch Surg. 2019; 404: 231-242
        • Seitz U.
        • Bohnacker S.
        • Seewald S.
        • et al.
        Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature.
        Dis Colon Rectum. 2004; 47 (discussion 96-7): 1789-1796
        • Kobayashi H.
        • Higuchi T.
        • Uetake H.
        • et al.
        Resection with en bloc removal of regional lymph node after endoscopic resection for T1 colorectal cancer.
        Ann Surg Oncol. 2012; 19: 4161-4167
        • Lowe D.
        • Saleem S.
        • Arif M.O.
        • Sinha S.
        • Brooks G.
        Role of endoscopic resection versus surgical resection in management of malignant colon polyps: a national cancer database analysis.
        J Gastrointest Surg. 2020; 24: 177-187
        • Cooper G.S.
        • Xu F.
        • Barnholtz Sloan J.S.
        • Koroukian S.M.
        • Schluchter M.D.
        Management of malignant colonic polyps: a population-based analysis of colonoscopic polypectomy versus surgery.
        Cancer. 2012; 118: 651-659
        • Charlson M.
        • Szatrowski T.P.
        • Peterson J.
        • Gold J.
        Validation of a combined comorbidity index.
        J Clin Epidemiol. 1994; 47: 1245-1251
        • Sun W.
        • Cheng M.
        • Zhuang S.
        • Qiu Z.
        Impact of insurance status on stage, treatment, and survival in patients with colorectal cancer: a population-based analysis.
        Med Sci Mon Int Med J Exp Clin Res. 2019; 25: 2397-2418
        • Zhang C.
        • Zhang C.
        • Wang Q.
        • Li Z.
        • Lin J.
        • Wang H.
        Differences in stage of cancer at diagnosis, treatment, and survival by race and ethnicity among leading cancer types.
        JAMA Netw Open. 2020; 3e202950
        • Sineshaw H.M.
        • Ng K.
        • Flanders W.D.
        • Brawley O.W.
        • Jemal A.
        Factors that contribute to differences in survival of Black vs white patients with colorectal cancer.
        Gastroenterology. 2018; 154 (e7): 906-915
        • Habr-Gama A.
        • Perez R.O.
        • Nadalin W.
        • et al.
        Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
        Ann Surg. 2004; 240 (discussion 7-8): 711-717
        • Lezoche E.
        • Baldarelli M.
        • Lezoche G.
        • Paganini A.M.
        • Gesuita R.
        • Guerrieri M.
        Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy.
        Br J Surg. 2012; 99: 1211-1218
        • Garcia-Aguilar J.
        • Renfro L.A.
        • Chow O.S.
        • et al.
        Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
        Lancet Oncol. 2015; 16: 1537-1546
        • Balyasnikova S.
        • Read J.
        • Tait D.
        • et al.
        The results of local excision with or without postoperative adjuvant chemoradiotherapy for early rectal cancer among patients choosing to avoid radical surgery.
        Colorectal Dis. 2017; 19: 139-147
        • Hrebinko K.A.
        • Reitz K.M.
        • Mohammed M.K.
        • et al.
        Transanal excision with adjuvant therapy for pT1N0 rectal tumors with high-risk features offers equivalent survival to radical resection: a National Cancer Database analysis.
        J Surg Oncol. 2021; 125: 475-483
        • Bach S.P.
        • Gilbert A.
        • Brock K.
        • et al.
        Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.
        Lancet Gastroenterol Hepatol. 2021; 6: 92-105
        • Benson A.B.
        • Venook A.P.
        • Al-Hawary M.M.
        • et al.
        NCCN guidelines insights: rectal cancer, version 6.2020.
        J Natl Compr Cancer Netw. 2020; 18: 806-815